Drug Profile
Methylphenidate extended-release oral suspension - Tris Pharma
Alternative Names: NWP 06; Quillivant ER; Quillivant XRLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator NextWave Pharmaceuticals
- Developer Tris Pharma
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
Most Recent Events
- 25 Sep 2023 Registered for Attention-deficit hyperactivity disorder (In children) in Canada (PO)
- 25 Sep 2023 KYE Pharmaceuticals intends to launch methylphenidate extended-release suspension (Quillivant® ER) in Canada in first quarter of 2024
- 01 Dec 2022 Methylphenidate extended-release oral suspension licensed to Pediatrix Therapeutics in China